Swiss pharmaceutical company Roche announced on Tuesday that it will invest $50 billion in the United States over the next five years. The investment aims to expand the company’s existing U.S.-based manufacturing and research and development (R&D) infrastructure while strengthening its next-generation therapeutic portfolio.
Roche expects the investment to create more than 12,000 new jobs in the U.S., including 1,000 direct hires. Over 6,500 of these positions will be in construction-related fields. The company currently employs more than 25,000 people across the United States.
The investment will include comprehensive facility upgrades and expansions at Roche’s manufacturing and distribution sites in Kentucky, Indiana, New Jersey, Oregon, and California. Additionally, a state-of-the-art gene therapy manufacturing facility will be established in Pennsylvania.
Roche plans to build a new manufacturing center spanning 900,000 square feet (approximately 84,000 square meters) to expand its portfolio of next-generation obesity treatments. The specific location will be announced later.
In Indiana, a new production facility for continuous glucose monitoring (CGM) devices will be constructed, while Massachusetts will become home to a new AI-powered R&D center. This center will focus on research in cardiovascular, renal, and metabolic diseases.
Roche Group CEO Thomas Schinecker stated that Roche, a Swiss company with a strong legacy in over 130 countries, is reaffirming its long-standing commitment to research, development, and manufacturing in the United States through this investment.
Once all new manufacturing capabilities are fully operational, Roche expects to produce and export more pharmaceutical products from the U.S. than it imports. The company’s diagnostics division already reports a trade surplus, exporting more from the U.S. than it imports from other countries.
